Assessing vision measurement methods for patients with retinal degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on evaluating the operational feasibility and measurement properties of efficacy endpoints for patients suffering from various retinal degenerations, including Retinitis Pigmentosa and Stargardt Disease. Conducted at the Vision Research and Assessment Institute, the study involves a prospective cohort of up to 40 patients for each condition, who will undergo a series of vision tests over a year. The aim is to understand how well patients utilize their vision in daily activities and to assess the impact of disease progression on their visual capabilities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records
* Best-corrected visual acuity between 20/70 and HM in at least one eye as tested with clinic-based visual acuity method
* Reasonably fluent in English

Exclusion Criteria:

* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
* Current pregnancy as reported by patient

Where it's running

• Vision Research and Assessment Institute
  Irvine, California, United States Recruiting

Study contacts

• Study coordinator: Shawn Yu, OD
• Email: info@vr-ai.com
• Phone: 949-264-3793

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Functional visual field and navigation testing for moderate-to-profound inherited retinal disease

  This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.

  Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT07502664

• Disulfiram (Antabuse) for vision in retinal degeneration

  This study will test whether taking oral disulfiram (Antabuse) improves vision in adults with retinal degeneration who are also being treated for alcohol use disorder.

  Recruiting Phase 1 University of Rochester · Rochester, New York · NCT06319872

• Registry for inherited retinal degenerative diseases

  This study is creating a registry for people with rare inherited eye diseases to help track their health and experiences over time, making it easier to understand these conditions and support research.

  Recruiting Foundation Fighting Blindness · Columbia, Maryland · NCT02435940

• ASP2020 eye injection safety in Stargardt-type macular dystrophy

  A small study will test whether a single ASP2020 eye injection is safe and may help people with Stargardt-type macular dystrophy.

  Recruiting at 4 sites Phase 1 Astellas Pharma Inc · Phoenix, Arizona and 3 other locations · NCT07734064

• Tracking how Stargardt-type macular dystrophy progresses in children and adults

  This project will follow children and adults with Stargardt-type macular dystrophies over time to see how their vision and eye findings change.

  Recruiting at 15 sites Astellas Pharma Inc · Phoenix, Arizona and 14 other locations · NCT07425574

• Evaluating a new gene therapy for Stargardt Disease

  This study is testing a new gene therapy to see if it can safely help people with Stargardt Disease Type 1 slow down or improve their vision loss.

  Recruiting at 5 sites Phase 1/2 Splice Bio · Aurora, Colorado and 4 other locations · NCT06942572

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.